皮膚癌治療市場按藥物類型、癌症類型、給藥途徑、分銷管道和地區分類

皮膚癌藥物市場規模預計在 2025 年達到 103 億美元，預計到 2032 年將達到 180 億美元，2025 年至 2032 年的複合年成長率為 8.3%。

皮膚癌是一種影響皮膚細胞的癌症，主要由暴露於太陽或日光浴床的紫外線 (UV) 輻射引起。它是全球最常見的癌症之一，且發生率逐年上升。為了應對這一成長趨勢，製藥公司正致力於開發和創新治療皮膚癌的藥物。

市場動態：

皮膚癌藥物市場的成長主要源自於全球皮膚癌發生率的上升。過度暴露於紫外線、生活方式的改變以及人口老化等因素都導致了皮膚癌發病率的上升。此外，治療性介入的進步和標靶治療的引入也進一步推動了市場的成長。

然而，市場擴張仍面臨許多挑戰。高昂的藥物開發成本和嚴格的監管要求是新參與企業面臨的主要障礙。此外，某些藥物的副作用以及替代治療方案的可用性也限制市場的成長。

儘管面臨諸多挑戰，市場仍蘊藏著許多成長機會。研發投入的增加以及製藥公司與研究機構之間合作的加強，預計將推動創新和新型治療方案的推出。此外，個人化醫療和聯合治療的日益普及也為市場擴張提供了潛力。

本研究的主要特點

• 本報告對全球皮膚癌治療市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。
• 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
• 它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球皮膚癌治療藥物市場的主要企業概況。
• 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
• 全球皮膚癌藥物市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過用於分析全球皮膚癌治療藥物市場的各種策略矩陣來更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
  • 皮膚癌發生率增加
  • 標靶治療高成本
  • 聯合治療
• 主要亮點
• 監管情景
• 近期動態
• 產品發布/核准
• PEST分析
• 波特分析
• 合併、收購和合作

4. 全球皮膚癌藥物市場-冠狀病毒（COVID-19）大流行的影響

• COVID-19流行病學
• 供需側分析
• 經濟影響

5. 2020 年至 2032 年全球皮膚癌藥物市場（依藥物類型）

• 化療藥物
• 標靶治療
• 免疫療法
• 荷爾蒙療法
• 其他（動態療法、冷凍療法等）

6. 2020 年至 2032 年全球皮膚癌藥物市場（依癌症類型分類）

• 基底細胞癌
• 鱗狀細胞癌
• 黑色素瘤
• 其他（卡波西氏肉瘤、蕈狀肉芽腫等）

7. 2020 年至 2032 年按給藥途徑分類的全球皮膚癌藥物市場

• 局部的
• 口服
• 注射
• 其他（手術、放射治療等）

8. 全球皮膚癌藥物市場（依通路分類），2020-2032 年

• 醫院藥房
• 零售藥局
• 網路藥局

9. 2020-2032 年全球皮膚癌藥物市場（按地區）

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太地區
• 中東
  • GCC
  • 以色列
  • 其他中東地區
• 非洲
  • 南非
  • 北非
  • 中部非洲

第10章 競爭格局

• 公司簡介
  • Novartis
  • Merck
  • Roche
  • Amgen
  • Pfizer
  • Sun Pharma
  • Bristol-Myers Squibb
  • AstraZeneca
  • Johnson &Johnson
  • Valeant
  • Daiichi Sankyo
  • Takeda Pharmaceutical
• 有限公司
  • LEO Pharma
  • Mylan NV
  • Sanofi
  • Regeneron
  • Eli Lilly
  • Bayer
  • Gilead Sciences
  • Astellas Pharma

第 11 章 章節

• 參考
• 調查方法
• 關於出版商

Skin Cancer Drugs Market is estimated to be valued at USD 10.3 Bn in 2025 and is expected to reach USD 18.00 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.

Skin cancer is a type of cancer that affects the skin cells and is primarily caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds. It is one of the most prevalent cancers globally, and its incidence has been increasing over the years. To combat this rising trend, pharmaceutical companies have been focusing on the development and innovation of skin cancer drugs.

Market Dynamics:

The skin cancer drugs market is primarily driven by the rising incidence of skin cancer worldwide. Factors such as excessive exposure to UV radiation, changing lifestyles, and an aging population contribute to the increasing prevalence of the disease. Moreover, advancements in therapeutic interventions and the introduction of targeted therapies have further fueled market growth.

However, there are several challenges that hinder the market's expansion. High drug development costs and stringent regulatory requirements pose significant barriers for new entrants. Additionally, adverse side effects associated with certain drugs and the availability of alternative treatment options act as restraining factors for market growth.

Despite these challenges, the market presents several opportunities for growth. Increasing investments in research and development activities, along with collaborations between pharmaceutical companies and research institutions, are expected to drive innovation and the introduction of novel treatment options. Moreover, the growing focus on personalized medicine and the use of combination therapies offer potential avenues for market expansion.

Key features of the study:

• This report provides in-depth analysis of the global skin cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global skin cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis, Merck, Roche, Amgen, Pfizer, Sun Pharma, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, Valeant, and others
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global skin cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin cancer drugs market

Detailed Segmentation:

• By Type
  • Melanoma Drugs
  • Non-Melanoma Skin Cancer Drugs
  • Actinic Keratosis Drugs
  • Others
• By Route of Administration
  • Topical
  • Oral
  • Injectable
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
• By Mechanism of Action
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Photodynamic Therapy
  • Others
• By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profiles
  • Novartis
  • Merck
  • Roche
  • Amgen
  • Pfizer
  • Sun Pharma
  • Bristol-Myers Squibb
  • AstraZeneca
  • Johnson & Johnson
  • Valeant
  • Daiichi Sankyo
  • Takeda
  • LEO Pharma
  • Mylan
  • Sanofi
  • Regeneron
  • Eli Lilly
  • Bayer
  • Gilead Sciences
  • Astellas Pharma

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Cancer Type
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing incidence of skin cancers
  • High costs of targeted therapies
  • Combination therapies
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Skin Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Skin Cancer Drugs Market, By Drug Type, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Chemotherapy Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Targeted Therapy Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Immunotherapy Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Hormone Therapy Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others (Photodynamic Therapy, Cryotherapy and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Skin Cancer Drugs Market, By Cancer Type, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Basal cell carcinoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Squamous cell carcinoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Melanoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others (Kaposi's sarcoma, Mycosis fungoides and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Skin Cancer Drugs Market, By Route of Administration, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others (Surgical procedures, radiation therapy and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Skin Cancer Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Skin Cancer Drugs Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Sub-region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Sub-region, 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Company Profile
  • Novartis
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Merck
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Roche
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Amgen
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Pfizer
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Sun Pharma
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Bristol-Myers Squibb
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • AstraZeneca
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Johnson & Johnson
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Valeant
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Daiichi Sankyo
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Takeda Pharmaceutical
• Company Limited
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • LEO Pharma
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Mylan N.V.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Sanofi
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Regeneron
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Eli Lilly
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Bayer
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Gilead Sciences
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Astellas Pharma
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Analyst Views

11. Section

• References
• Research Methodology
• About us